Previous Close | 55.43 |
Open | 55.49 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 54.00 - 55.49 |
52 Week Range | 23.28 - 57.30 |
Volume | 430,230 |
Avg. Volume | 359,845 |
Market Cap | 2.054B |
Beta | 1.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.24 |
Earnings Date | May 8, 2018 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 60.29 |
Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2018 financial results after market close on Tuesday, May 8, 2018. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions.
NEW YORK, April 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Investors in Quidel (QDEL) need to pay close attention to the stock based on moves in the options market lately.
NEW YORK, March 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will host its 2018 Quidel Analyst and Investor Day at the Hyatt Regency O’Hare hotel in Chicago, Illinois on Tuesday, April 3, 2018.
Quidel (QDEL) needs investors to pay close attention to the stock based on moves in the options market lately.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 .
Diagnostic healthcare products manufacturer Quidel Corporation (NASDAQ: QDEL )'s shares are not fully reflecting the company's growth potential and likely positive estimate revision bias, according to ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! H & R Block Inc (NYSE: HRB ) stock gained more than ...
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510 clearance from the United States Food and Drug Administration to market its Sofia Lyme FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to ...
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will p
Q4 2017 Quidel Corp Earnings Call
The San Diego-based company said it had a loss of 15 cents per share. Losses, adjusted for pretax expenses, were 11 cents per share. The medical diagnostics company posted revenue of $114.9 million in ...
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2017.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510 clearance from the United States Food and Drug Administration for Quidel’s CLIA Waived QuickVue® Influenza A+B assay for the rapid, differential detection of influenza types A and B.
Surging implied volatility makes Quidel (QDEL) stock lucrative to the option traders.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fourth quarter and full year 2017 financial results after market close on Wednesday, February 21, 2018.
NEW YORK, Jan. 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Quidel ...
Investors in Quidel (QDEL) need to pay close attention to the stock based on moves in the options market lately.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has completed the sale leaseback transaction for the Alere San Diego property on Summers Ridge Road that was acquired as part of the Triage Business from Alere, Inc.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it has received 510 clearance and Clinical Laboratory Improvements Amendments waiver from the United States Food and Drug Administration for its Sofia Strep A+ Fluorescent Immunoassay to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for ...
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it has received 510 clearance from the United States Food and Drug Administration for its Solana® GBS Assay for the direct, qualitative detection of Group B Streptococcus from enriched broth cultures of specimens from antepartum women.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 36th Annual J.P.
Quidel Corporation , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today filed the Company’s required report on Form 8-K/A with the Securities and Exchange Commission after market close.